Novocure Receives FDA Approval for Second Generation Optune System Second generation Optune system is less than half the weight and size of first generation Optune system New system aims to make ...
The FDA has approved a lighter and more convenient version of the tumor-treating field device Optune for patients with glioblastoma multiforme. The FDA has approved a lighter and more convenient ...
ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have released a final local ...
ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that the State of Israel Ministry of Health has added Optune in combination with temozolomide to the Israeli medical ...
The U.S. Food and Drug Administration today approved an expanded indication for the Optune device to treat patients with newly-diagnosed glioblastoma multiforme (GBM), an aggressive form of brain ...
Optune Lua, formerly known as NovoTTF-100L, is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) ...
St. Helier, NJ's Novocure ($NVCR) submitted a PMA supplement with the FDA, in hopes of marketing an upgraded version of its noninvasive Optune system to treat ...
The glut of data released at the AACR meeting on Novocure’s (NVCR) Optune device in various hard-to-treat cancers has caused the company’s shares to pop by 37%. The system, which emits electric fields ...
The approval was based on findings from the phase 3 EF-14 trial. The FDA has expanded the indication for Optune (NovoTTF-100A System) in combination with Temodar (temozolomide) as a treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results